Ocugen, Inc. (OCGN)
After hours:
| Previous close | 1.8700 |
| Open | 1.8100 |
| Bid | 0.0000 x 2200 |
| Ask | 0.0000 x 40700 |
| Day's range | 1.7650 - 1.8650 |
| 52-week range | 1.6700 - 17.6500 |
| Volume | |
| Avg. volume | 5,273,406 |
| Market cap | 398.481M |
| Beta (5Y monthly) | 4.22 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3470 |
| Earnings date | 07 Nov 2022 - 11 Nov 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.83 |
- GlobeNewswire
Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference
MALVERN, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen, will participate in an in-person fireside chat at the Chardan 6th Annual Genetic Medicines Conference being held October 3-4, 2022 in New York, NY. Details regarding D
- GlobeNewswire
Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan
Ocugen’s intranasal candidate is one of the world’s most advanced intranasal COVID-19 vaccinesIntranasal vaccine is designed to curb virus transmission and confer protective immunity MALVERN, Pa., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that the company has entered into an exclusive license agreement with Washington Universit
- GlobeNewswire
Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MALVERN, Pa., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the Compensation Committee of the Board of Directors of Ocugen approved the grant of stock options to purchase an aggregate of 148,800 shares of its common stock and restricted stock units (RSUs) covering an aggregate of 40,092 shares of common stock to five
